http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Kymera Therapeutics (KYMR) Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413
-
Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413
-
Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, Compared to Small Molecule Inhibitor in Preclinical Leukemia Model
-
Kymera Therapeutics to Participate in Upcoming June Investor Conference
-
Kymera Therapeutics (KYMR) Appoints Jeremy Chadwick as COO
-
Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer
-
Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253
-
Kymera Therapeutics (KYMR) Presents Clinical Data from the Phase 1 Trial on KT-474
-
Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium
-
Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update
-
Kymera Therapeutics to Report First Quarter 2023 Financial Results on May 4
-
Kymera Therapeutics to Report First Quarter 2023 Financial Results on May 4
-
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
-
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
-
Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
-
Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
-
Kymera Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 23
-
Kymera Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 23
-
X-Chem and Kymera Expand Existing Partnership
-
Kymera Therapeutics (KYMR) Shares Key 2023 Goals
-
Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company
-
Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company
-
Kymera Appoints Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary
-
Kymera Appoints Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary
-
Kymera Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023
-
Kymera Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023
-
Kymera Therapeutics (KYMR) Announces Positive Results from Phase 1 Clinical Trial Evaluating KT-474 in Patients with HS and AD and Sanofi's Decision to Advance KT-474 into Phase 2 Clinical Trials
-
Kymera Announces Positive Results from Phase 1 Clinical Trial Evaluating KT-474 in Patients with HS and AD and Sanofi’s Decision to Advance KT-474 into Phase 2 Clinical Trials
-
Kymera Announces Positive Results from Phase 1 Clinical Trial Evaluating KT-474 in Patients with HS and AD and Sanofi’s Decision to Advance KT-474 into Phase 2 Clinical Trials
-
Kymera Therapeutics (KYMR) Announces Preclinical Data from Collaborations Demonstrate Therapeutic Potential of STAT3 Degraders in CTCL and IRAKIMiD Combination with BCL-2 Inhibitor in MYD88-Mutant DLB
-
Preclinical Data from Kymera Therapeutics’ Collaborations Demonstrate Therapeutic Potential of STAT3 Degraders in CTCL and IRAKIMiD Combination with BCL-2 Inhibitor in MYD88-Mutant DLBCL at the Amer
-
Preclinical Data from Kymera Therapeutics’ Collaborations Demonstrate Therapeutic Potential of STAT3 Degraders in CTCL and IRAKIMiD Combination with BCL-2 Inhibitor in MYD88-Mutant DLBCL at the Amer
-
Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Mee
-
Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Mee
-
Kymera Therapeutics Provides Webcast Information for December 14 Investor Event
-
Kymera Therapeutics Provides Webcast Information for December 14 Investor Event
-
Kymera Therapeutics (KYMR) Appoints Victor Sandor to its Board
-
Kymera Therapeutics Appoints Biopharmaceutical Leader Victor Sandor, M.D.C.M., to Board of Directors
-
Kymera Therapeutics Appoints Biopharmaceutical Leader Victor Sandor, M.D.C.M., to Board of Directors
-
Kymera Therapeutics to Report Third Quarter 2022 Results on November 3
-
Kymera Therapeutics to Report Third Quarter 2022 Results on November 3
-
Kymera Therapeutics to Hold Investor Webcast on December 14 to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline
-
Kymera Therapeutics to Hold Investor Webcast on December 14 to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline
-
Kymera Therapeutics (KYMR) Granted FDA Orphan Drug Designation for KT-333
-
Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Cutaneous T-Cell Lymphoma
-
Kymera Therapeutics to Report Second Quarter 2022 Results on August 9
-
Kymera Therapeutics (KYMR) Appoints Leigh Morgan to its Board
-
Kymera Therapeutics Strengthens Board of Directors with Appointment of People and Business Leader Leigh Morgan
-
Kymera Therapeutics (KYMR) Doses First Patients in STAT3 and IRAKIMiD Degraders KT-333 and KT-413 Phase 1 Trial
-
Kymera Therapeutics Doses First Patients in Phase 1 Oncology Trials of STAT3 and IRAKIMiD Degraders KT-333 and KT-413
